Influence of bisphosphonates and cisplatin on MG-63 cell lines cultured in vitro

doi:10.3969/j.issn.2095-4344.2015.33.016

Abstract

Abstract:

BACKGROUND: Studies have shown that bisphosphonates can act on osteosarcoma cells, but the comparative analysis of bisphosphonates and cisplatin, a traditional first-line chemotherapy drug, is rarely reported.

OBJECTIVE: To investigate the differences between bisphosphonates and cisplatin to inhibit in vitro proliferation of osteosarcoma cells and induce cell apoptosis.

METHODS: Subcultured MG-63 cell lines were intervened with different concentrations of bisphosphonates and cisplatin, respectively, and cells with no treatment served as negative controls (blank group). Cell inhibition rate was detected using MTT method, and cell morphology was observed using fluorescent staining.

RESULTS AND CONCLUSION: After intervention with different concentrations of bisphosphonates and cisplatin for different time, the growth inhibition rate of MG-63 cells was significantly higher as compared with the blank group (P < 0.05). But there was no difference in the growth inhibition rate between the bisphosphonates and cisplatin groups at 24, 48 and 72 hours (P > 0.05). These findings indicate that bisphosphonates has obvious inhibitory effect on the growth of osteosarcoma cells in vitro, and its inhibitory effect is similar to that of cisplatin.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Diphosphonates, Cisplatin, Osteosarcoma

CLC Number:

R318

Maimaitiaili Hasimu, Aziguli, Jiang Ren-bing, Bai Jing-ping. Influence of bisphosphonates and cisplatin on MG-63 cell lines cultured in vitro[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(33): 5327-5331.

Figures/Tables 1

References

[1] 曲范杰,黄杰.二膦酸盐治疗恶性肿瘤骨转移的疗效分析[J].中华肿瘤学,2009,29(2): 118-119.
[2] 朱广迎.放射肿瘤学[M].北京:北京科学技术文献出版社,2009: 76-80.
[3] 勇昆,牛晓辉.骨肉瘤诊断、治疗、随访的ESMO临床指南[J].中国骨肿瘤骨病,2010,9(2):110-111．
[4] 刘琦,李晓阳,肖涛.骨肉瘤优化新辅助化疗方案临床疗效观察[J]中国医师杂志,2014,16(5):634-637
[5] Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis.2010; 89(3):411-417.
[6] Granchi D, Scarso A, Bianchini G,et al.Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.Eur J Med Chem. 2013;65:448-455.
[7] DE Iuliis F, Taglieri L, Amoroso L,et al.Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.Anticancer Res. 2014; 34(5): 2477-2480.
[8] Iguchi K,Nakano T,Usui S,et al.Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett,2006;237(2):223-233.
[9] Tassone P,Tagliaferri P,Viscomi C,et al.Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer.2011; 88(12): 1971-1978.
[10] Baulch BC,Molloy TJ,Yeh SL,et al.Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res.2010;31(3):341-352.
[11] Chang Z, Xing J, Yu X, et al. Curcumin induces osteosarcoma MG63 cells apoptosis via ROS/Cyto-C/Caspase-3 pathway. Tumour Biol.2014;35(1):753-758.
[12] Lauricella M, D'Anneo A, Giuliano M, et al.Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ. 2003;10(8):930-932.
[13] Jin S, Pang RP, Shen JN, et al. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis. 2007;12(7):1317-1326.
[14] Ito Y, Pandey P, Sporn MB,et al. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol. 2001;59(5):1094-1099.
[15] Zhang Y, Bhavnani BR.Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome c release. BMC Neurosci. 2005;6:13.
[16] Sangha R, Lara PN Jr, Adjei AA, et al. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009;10(5):322-330.
[17] Chen J, Ye L, Zhang L, et al. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol. 2009;35(1):159-166.
[18] Jesien-Lewandowicz E, Spych M, Fijuth J,et al. Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control. Lung Cancer. 2010; 69(2):245-246.
[19] Karczmarek-Borowska B, Zielińska K, Buka?a A,et al. Hyponatremia in the course of small cell lung cancer-a case report.organ Polskiego Towarzystwa Lekarskiego, 2014;37 (217):2852-2856.
[20] Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008;22(13):1486-1492.
[21] Xenidis N, Kotsakis A, Kalykaki A,et al.Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Lung Cancer. 2010 ;68(3):1145-1148.
[22] Usuda J, Ichinose S, Ishizumi T, et al. Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery. Lung Cancer. 2011;74(2): 332-337.
[23] Li Y, Xu J, Mao L, et al.Allogeneic mesenchymal stem cell therapy for bisphosphonate•related jaw osteonecrosis in Swine．Stem Cells Dev.2013;22(14):2047-2056．
[24] Chen QY, zheng Y, Jiao DM, et al. Curumin in hibits lung cancer cell migration and invasion through racl dependent signaling pathway.Nutrbiochem 2014;25(2):177-185.
[25] Busch AM, Johnson KC, Stan RN, et al. Evidence for tankyrases as antine tineoplastic targets in lung cancer.BMC Cancer.2013;13:211.
[26] Lau T, Chan E, Callow M, et al. A novel tankyrase small molecule inhibitor suppresses APC mutation driven colorectal tumor growth.Cancer Res. 2013;73(10):3132-3144
[27] Foerster R, Eisele C, Bruckner T, et al. Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis. Radiat Oncol.2015;10:62.
[28] Khorasani MS, Diko S, Hsia AW, .et al. Christiansen Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther. 2015;17:30
[29] Reynolds K,Viswanathan HN,Muntner P,et al.O'Malley Quality of life research，Validation of the Osteoporosis- Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates.Qual Life Res.2014;23(7): 2109-2120.
[30] Lubwama R, Nguyen A, Modi A, et al.Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: is treatment with bisphosphonates an option? Osteoporos Int. 2014;25(5):1607-1615.